Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19
10.13422/j.cnki.syfjx.20201321
- VernacularTitle:热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察
- Author:
Ming-bo YANG
1
;
Shuang-suo DANG
2
;
Sheng HUANG
3
;
Yuan-jun LI
4
;
Ya-ling GUO
1
Author Information
1. Xi'anNo. 8 Hospital, Xi'an710061, China
2. The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an710004, China
3. Songzi People's Hospital, Songzi434200, China
4. Yan'an Second People's Hospital, Yan'an716000, China
- Publication Type:Research Article
- Keywords:
Reyanning mixture;
coronavirus disease-2019 (COVID-19);
clinical symptoms
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(14):7-12
- CountryChina
- Language:Chinese
-
Abstract:
Objective:In the early stage, in vivo experiments of coronavirus infection and pulmonary syndrome syndrome combined with mouse model verified that Reyanning mixture has a significant therapeutic effect on human coronavirus disease-2019 (COVID-19). This study further evaluated the clinical efficacy of Reyanning mixture in the treatment of COVID-19, providing a basis for clinical medication. Method:Patients were collected from January 21, 2020 to February 24, 2020 in Xi'an No. 8 Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, Yan'an Second People's Hospital and Songzi People's Hospital. 54 common-type patients who met the diagnostic criteria of COVID-19 were enrolled in this study,5 patients of them were not included in the statistical analysis because they did not meet the requirements, including 26 cases in the treatment group using Reyanning mixture on the basis of chemical drug treatment, and 23 cases in the control group receiving chemical drug treatment only. The symptom disappearance rates (throat dryness, throat pain, cough, fever, fatigue, chest tightness, runny nose, nasal congestion, headache), time to complete fever clearance (d), the nucleic acid conversion rate and time to recovery on chest CT were compared between two groups. Result:After treatment, except cough and fatigue, other symptoms disappeared in the treatment group, and the disappearance rate of symptoms such as dry throat, cough, fatigue, chest tightness and headache was statistically significant compared with the control group (P<0.05). The median time to complete fever clearance in the treatment group was 3 days, which was 2 days shorter than that in control group. The remission rate of chest CT was 88.46% (23/26) in the treatment group, which was higher than 73.91% (17/23) in control group. The negative conversion rate of viral nucleic acid detection was 96.15% (25/26) in treatment group, higher than 60.87% (14/23) in control group (P<0.01). Conclusion:Reyanning mixture can improve the clinical symptoms of COVID-19 patients, promote the improvement of chest CT. Can shorten the duration of fever.Can improve the novel coronavirus nucleic acid conversion rate, providing a basis for clinical treatment.
